Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1995 1
1997 1
1998 1
2000 1
2001 5
2002 7
2003 1
2004 4
2005 2
2006 5
2007 7
2008 6
2009 3
2010 5
2011 10
2012 11
2013 8
2014 10
2015 22
2016 18
2017 10
2018 8
2019 10
2020 6
2021 6
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 24502602

150 results

Results by year

Filters applied: . Clear all
Page 1
Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant.
Warsame R, Bang SM, Kumar SK, Gertz MA, Lacy MQ, Buadi F, Dingli D, Hayman SR, Kapoor P, Kyle RA, Leung N, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, Rajkumar SV, Dispenzieri A. Warsame R, et al. Eur J Haematol. 2014 Jun;92(6):485-90. doi: 10.1111/ejh.12282. Epub 2014 Mar 2. Eur J Haematol. 2014. PMID: 24502602
Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis.
Tandon N, Sidana S, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Fonder AL, Hobbs MA, Hayman SR, Gonsalves WI, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Russell SJ, Zeldenrust SR, Rajkumar SV, Kumar SK. Tandon N, et al. Am J Hematol. 2017 Jun;92(6):549-554. doi: 10.1002/ajh.24723. Epub 2017 Apr 26. Am J Hematol. 2017. PMID: 28314084 Free article.
A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.
Cibeira MT, Oriol A, Lahuerta JJ, Mateos MV, de la Rubia J, Hernández MT, Granell M, Fernández de Larrea C, San Miguel JF, Bladé J; PETHEMA cooperative study group. Cibeira MT, et al. Br J Haematol. 2015 Sep;170(6):804-13. doi: 10.1111/bjh.13500. Epub 2015 May 14. Br J Haematol. 2015. PMID: 25974382 Free article. Clinical Trial.
Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis.
Hwa YL, Warsame R, Gertz MA, Buadi FK, Lacy MQ, Kumar SK, Dingli D, Zeldenrust SR, Leung N, Hayman SR, Kapoor P, Gonsalves WI, Kourelis TV, Russell S, Go RS, Hobbs MA, Fonder AL, Rajkumar SV, Dispenzieri A. Hwa YL, et al. Blood. 2017 Sep 28;130(13):1578-1584. doi: 10.1182/blood-2017-05-783415. Epub 2017 Aug 14. Blood. 2017. PMID: 28807981 Free article.
Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation.
Herrmann SM, Gertz MA, Stegall MD, Dispenzieri A, Cosio FC, Kumar S, Lacy MQ, Dean PG, Prieto M, Zeldenrust SR, Buadi FK, Russell SJ, Nyberg SL, Hayman SR, Dingli D, Fervenza FC, Leung N. Herrmann SM, et al. Nephrol Dial Transplant. 2011 Jun;26(6):2032-6. doi: 10.1093/ndt/gfr067. Epub 2011 May 4. Nephrol Dial Transplant. 2011. PMID: 21543655
Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation.
Afrough A, Saliba RM, Hamdi A, El Fakih R, Varma A, Dinh YT, Rondon G, Cornelison AM, Shah ND, Bashir Q, Shah JJ, Hosing C, Popat U, Orlowski RZ, Champlin RE, Parmar S, Qazilbash MH. Afrough A, et al. Biol Blood Marrow Transplant. 2015 Aug;21(8):1413-7. doi: 10.1016/j.bbmt.2015.03.025. Epub 2015 Apr 2. Biol Blood Marrow Transplant. 2015. PMID: 25842049 Free PMC article.
Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H, Levine B, Filippa DA, Riedel E, Kewalramani T, Stubblefield MD, Fleisher M, Nimer S, Comenzo RL. Cohen AD, et al. Br J Haematol. 2007 Oct;139(2):224-33. doi: 10.1111/j.1365-2141.2007.06783.x. Br J Haematol. 2007. PMID: 17897298 Free article. Clinical Trial.
150 results